Advertisement

Special Considerations in Patients with Early-Stage Breast Cancer and Survivors

  • Jessica F. Partin
    Correspondence
    Carilion Clinic Department of Surgery, 3 Riverside Circle, 4th floor, Roanoke, VA 24016, USA
    Affiliations
    Virginia Tech Carilion School of MedicineCarilion Clinic Department of Surgery, 3 Riverside Circle, 4th floor, Roanoke, VA 24016, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics data visualizations tool, based on 2019 submission data (1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2020.

      2. SEER∗Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Available at: https://seer.cancer.gov/explorer/.Accessed September 14, 2020

        • American Cancer Society
        (Available at:)
        • Waks A.G.
        • Winer E.P.
        Breast cancer treatment: a review.
        JAMA. 2019; 321: 288-300
        • Prat A.
        • Perou C.M.
        Deconstructing the molecular portraits of breast cancer.
        Mol Oncol. 2011; 5: 5-23
        • Prat A.
        • Pineda E.
        • Adamo B.
        • et al.
        Clinical implications of the intrinsic molecular subtypes of breast cancer.
        Breast. 2015; 24: S26-S35
        • Overmoyer B.
        Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?.
        J Clin Oncol. 2015; 33: 823-828
        • Perou C.M.
        • Sørlie T.
        • Eisen M.B.
        • et al.
        Molecular portraits of human breast tumours.
        Nature. 2000; 406: 747-752
        • Sørlie T.
        • Perou C.M.
        • Tibshirani R.
        • et al.
        Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
        Proc Natl Acad Sci U S A. 2001; 98: 10869-10874
        • Cancer Genome Atlas Network
        Comprehensive molecular portraits of human breast tumours.
        Nature. 2012; 490: 61-70
        • Ronchi A.
        • Pagliuca F.
        • Zito Marino F.
        • et al.
        Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma.
        Semin Cancer Biol. 2021; 72: 114-122
        • Bosserman L.D.
        • Cianfrocca M.
        • Yuh B.
        • et al.
        Integrating academic and community cancer care and research through multidisciplinary oncology pathways for value-based care: a review and the city of hope experience.
        J Clin Med. 2021; 10: 188
        • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
        Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 365: 1687-1717
        • Janni W.
        • Hepp P.
        Adjuvant aromatase inhibitor therapy: outcomes and safety.
        Cancer Treat Rev. 2010; 36: 249-261
        • Krauss K.
        • Stickeler E.
        Endocrine therapy in early breast cancer.
        Breast Care (Basel). 2020; 15: 337-346
        • Harris L.N.
        • Ismaila N.
        • McShane L.M.
        • et al.
        Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
        J Clin Oncol. 2016; 34: 1134-1150
        • Markopoulos C.
        • Hyams D.M.
        • Gomez H.L.
        • et al.
        Multigene assays in early breast cancer: Insights from recent phase 3 studies.
        Eur J Surg Oncol. 2020; 46: 656-666
        • Giorgi Rossi P.
        • Lebeau A.
        • Canelo-Aybar C.
        • et al.
        Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative [published online ahead of print, 2021 Feb 18].
        Br J Cancer. 2021; https://doi.org/10.1038/s41416-020-01247-z
        • Lüftner D.
        • Bauerfeind I.
        • Braun M.
        • et al.
        Treatment of early breast cancer patients: evidence, controversies, consensus: focusing on systemic therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
        Breast Care (Basel). 2019; 14: 315-324
        • Moja L.
        • Tagliabue L.
        • Balduzzi S.
        • et al.
        Trastuzumab containing regimens for early breast cancer.
        Cochrane Database Syst Rev. 2012; 2012: CD006243
        • Pernas S.
        • Barroso-Sousa R.
        • Tolaney S.M.
        Optimal treatment of early stage HER2-positive breast cancer.
        Cancer. 2018; 124: 4455-4466
        • Ban M.
        • Petrić Miše B.
        • Vrdoljak E.
        Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches.
        Breast Care (Basel). 2020; 15: 560-569
        • Cortazar P.
        • Zhang L.
        • Untch M.
        • et al.
        Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
        Lancet. 2014; 384 ([Erratum appears in Lancet 2019;393(10175):986]): 164-172
        • Jagsi R.
        • Li Y.
        • Morrow M.
        • et al.
        Patient-reported quality of life and satisfaction with cosmetic outcomes after breast conservation and mastectomy with and without reconstruction: results of a survey of breast cancer survivors.
        Ann Surg. 2015; 261: 1198-1206
        • Fisher B.
        • Anderson S.
        • Bryant J.
        • et al.
        Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
        N Engl J Med. 2002; 347: 1233-1241
        • Veronesi U.
        • Cascinelli N.
        • Mariani L.
        • et al.
        Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.
        N Engl J Med. 2002; 347: 1227-1232
        • Litière S.
        • Werutsky G.
        • Fentiman I.S.
        • et al.
        Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.
        Lancet Oncol. 2012; 13: 412-419
        • Agarwal S.
        • Pappas L.
        • Neumayer L.
        • et al.
        Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer.
        JAMA Surg. 2014; 149: 267-274
        • Wrubel E.
        • Natwick R.
        • Wright G.P.
        Breast-conserving therapy is associated with improved survival compared with mastectomy for early-stage breast cancer: a propensity score matched comparison using the National Cancer Database.
        Ann Surg Oncol. 2021; 28: 914-919
        • Moo T.A.
        • Sanford R.
        • Dang C.
        • et al.
        Overview of breast cancer therapy.
        PET Clin. 2018; 13: 339-354
        • Park S.
        • Koo J.S.
        • Kim M.S.
        • et al.
        Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
        Breast. 2012; 21: 50-57
        • Voduc K.D.
        • Cheang M.C.
        • Tyldesley S.
        • et al.
        Breast cancer subtypes and the risk of local and regional relapse.
        J Clin Oncol. 2010; 28: 1684-1691
        • Lowery A.J.
        • Kell M.R.
        • Glynn R.W.
        • et al.
        Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.
        Breast Cancer Res Treat. 2012; 133: 831-841
        • Wang J.
        • Xie X.
        • Wang X.
        • et al.
        Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis.
        Surg Oncol. 2013; 22: 247-255
        • Taylor C.
        • Correa C.
        • Duane F.K.
        • et al.
        Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials.
        J Clin Oncol. 2017; 35: 1641-1649
        • Darby S.C.
        • Ewertz M.
        • McGale P.
        • et al.
        Risk of ischemic heart disease in women after radiotherapy for breast cancer.
        N Engl J Med. 2013; 368: 987-998
        • Gupta A.
        • Ohri N.
        • Haffty B.G.
        Hypofractionated radiation treatment in the management of breast cancer.
        Expert Rev Anticancer Ther. 2018; 18: 793-803
        • Whelan T.J.
        • Pignol J.P.
        • Levine M.N.
        • et al.
        Long-term results of hypofractionated radiation therapy for breast cancer.
        N Engl J Med. 2010; 362: 513-520
        • Lanni T.
        • Keisch M.
        • Shah C.
        • et al.
        A cost comparison analysis of adjuvant radiation therapy techniques after breast-conserving surgery.
        Breast J. 2013; 19: 162-167
        • Goldberg M.
        • Whelan T.J.
        Accelerated partial breast irradiation (APBI): where are we now?.
        Curr Breast Cancer Rep. 2020; : 1-10https://doi.org/10.1007/s12609-020-00384-x
        • Esposito E.
        • Anninga B.
        • Harris S.
        • et al.
        Intraoperative radiotherapy in early breast cancer.
        Br J Surg. 2015; 102: 599-610
        • Correa C.
        • Harris E.E.
        • Leonardi M.C.
        • et al.
        Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement.
        Pract Radiat Oncol. 2017; 7: 73-79
        • Hughes K.S.
        • Schnaper L.A.
        • Bellon J.R.
        • et al.
        Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
        J Clin Oncol. 2013; 31: 2382-2387
        • Moran M.S.
        • Schnitt S.J.
        • Giuliano A.E.
        • et al.
        Society of Surgical Oncology-American Society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.
        Int J Radiat Oncol Biol Phys. 2014; 88: 553-564
        • Waljee J.F.
        • Hu E.S.
        • Ubel P.A.
        • et al.
        Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life.
        J Clin Oncol. 2008; 26: 3331-3337
        • Nano M.T.
        • Gill P.G.
        • Kollias J.
        • et al.
        Psychological impact and cosmetic outcome of surgical breast cancer strategies.
        ANZ J Surg. 2005; 75: 940-947
        • Kim M.K.
        • Kim T.
        • Moon H.G.
        • et al.
        Effect of cosmetic outcome on quality of life after breast cancer surgery.
        Eur J Surg Oncol. 2015; 41: 426-432
        • Centers for Medicare & Medicaid Services
        Programs and Initiatives, Insurance Protections.
        (Available at:) (Accessed March 2021)
        • Manahan E.R.
        • Kuerer H.M.
        • Sebastian M.
        • et al.
        Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons.
        Ann Surg Oncol. 2019; 26: 3025-3031
        • Piombino C.
        • Cortesi L.
        • Lambertini M.
        • et al.
        Secondary prevention in hereditary breast and/or ovarian cancer syndromes other than BRCA.
        J Oncol. 2020; 2020: 6384190
        • Chiba A.
        • Hoskin T.L.
        • Hallberg E.J.
        • et al.
        Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer.
        Ann Surg Oncol. 2016; 23: 3232-3238
        • Patnaik J.L.
        • Byers T.
        • Diguiseppi C.
        • et al.
        The influence of comorbidities on overall survival among older women diagnosed with breast cancer.
        J Natl Cancer Inst. 2011; 103: 1101-1111
        • Land L.H.
        • Dalton S.O.
        • Jensen M.B.
        • et al.
        Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer.
        Br J Cancer. 2012; 107: 1901-1907
        • Ewertz M.
        • Land L.H.
        • Dalton S.O.
        • et al.
        Influence of specific comorbidities on survival after early-stage breast cancer.
        Acta Oncol. 2018; 57: 129-134
        • Coughlin S.S.
        Social determinants of breast cancer risk, stage, and survival.
        Breast Cancer Res Treat. 2019; 177: 537-548
        • Vona-Davis L.
        • Rose D.P.
        The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.
        J Womens Health (Larchmt). 2009; 18: 883-893
        • Saini G.
        • Ogden A.
        • McCullough L.E.
        • et al.
        Disadvantaged neighborhoods and racial disparity in breast cancer outcomes: the biological link.
        Cancer Causes Control. 2019; 30: 677-686
        • Sharrocks K.
        • Spicer J.
        • Camidge D.R.
        • et al.
        The impact of socioeconomic status on access to cancer clinical trials.
        Br J Cancer. 2014; 111: 1684-1687
        • Schroeder S.R.
        • Agusala V.
        • Sher D.J.
        Financial Toxicity and Cancer Therapy: A Primer for Radiation Oncologists.
        Hematol Oncol Clin North Am. 2019; 33: 1117-1128
        • Mehnert A.
        Employment and work-related issues in cancer survivors.
        Crit Rev Oncol Hematol. 2011; 77: 109-130
        • Arozullah A.M.
        • Calhoun E.A.
        • Wolf M.
        • et al.
        The financial burden of cancer: estimates from a study of insured women with breast cancer.
        J Support Oncol. 2004; 2: 271-278
        • Pisu M.
        • Azuero A.
        • Benz R.
        • et al.
        Out-of-pocket costs and burden among rural breast cancer survivors.
        Cancer Med. 2017; 6: 572-581
        • Williams C.P.
        • Gallagher K.D.
        • Deehr K.
        • et al.
        Quantifying treatment preferences and their association with financial toxicity in women with breast cancer.
        Cancer. 2021; 127: 449-457
        • Greenup R.A.
        • Rushing C.
        • Fish L.
        • et al.
        Financial costs and burden related to decisions for breast cancer surgery.
        J Oncol Pract. 2019; 15: e666-e676
        • Selden C.
        • Zorn M.
        • Ratzan S.C.
        • et al.
        Health literacy (bibliography online).
        National Library of Medicine, Bethesda, MD2000 (Available at)
        • Berkman N.D.
        • Sheridan S.L.
        • Donahue K.E.
        • et al.
        Low health literacy and health outcomes: an updated systematic review.
        Ann Intern Med. 2011; 155: 97-107
        • Baker D.W.
        • Wolf M.S.
        • Feinglass J.
        • et al.
        Health literacy and mortality among elderly persons.
        Arch Intern Med. 2007; 167: 1503-1509
        • De Oliveira Jr., G.S.
        • McCarthy R.J.
        • Wolf M.S.
        • et al.
        The impact of health literacy in the care of surgical patients: a qualitative systematic review.
        BMC Surg. 2015; 15: 86
        • Hälleberg Nyman M.
        • Nilsson U.
        • Dahlberg K.
        • et al.
        Association between functional health literacy and postoperative recovery, health care contacts, and health-related quality of life among patients undergoing day surgery: secondary analysis of a randomized clinical trial.
        JAMA Surg. 2018; 153: 738-745
        • Keim-Malpass J.
        • Doede A.
        • Camacho F.
        • et al.
        Impact of patient health literacy on surgical treatment of breast cancer.
        Breast J. 2018; 24: 633-636
        • Brewer N.T.
        • Tzeng J.P.
        • Lillie S.E.
        • et al.
        Health literacy and cancer risk perception: implications for genomic risk communication.
        Med Decis Making. 2009; 29: 157-166
        • Chlebowski R.T.
        • Kim J.
        • Haque R.
        Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.
        Cancer Prev Res (Phila). 2014; 7: 378-387
        • Portelli Tremont J.N.
        • Downs-Canner S.
        • Maduekwe U.
        Delving deeper into disparity: The impact of health literacy on the surgical care of breast cancer patients.
        Am J Surg. 2020; 220: 806-810
        • Joly F.
        • Lange M.
        • Dos Santos M.
        • et al.
        Long-term fatigue and cognitive disorders in breast cancer survivors.
        Cancers (Basel). 2019; 11: 1896
        • Khan J.S.
        • Ladha K.S.
        • Abdallah F.
        • et al.
        Treating persistent pain after breast cancer surgery.
        Drugs. 2020; 80: 23-31
        • He L.
        • Qu H.
        • Wu Q.
        • et al.
        Lymphedema in survivors of breast cancer.
        Oncol Lett. 2020; 19: 2085-2096